Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H. Wen T, et al. Among authors: gicobi jk. Cancer Immunol Res. 2022 Feb;10(2):162-181. doi: 10.1158/2326-6066.CIR-21-0539. Epub 2021 Dec 15. Cancer Immunol Res. 2022. PMID: 34911739 Free PMC article.
Immune resilience in response to cancer therapy.
Gicobi JK, Barham W, Dong H. Gicobi JK, et al. Cancer Immunol Immunother. 2020 Nov;69(11):2165-2167. doi: 10.1007/s00262-020-02731-4. Cancer Immunol Immunother. 2020. PMID: 33011909 Free PMC article. No abstract available.
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors.
Barham W, Hsu M, Liu X, Harrington SM, Hirdler JB, Gicobi JK, Zhu X, Zeng H, Pavelko KD, Yan Y, Mansfield AS, Dong H. Barham W, et al. Among authors: gicobi jk. Immunohorizons. 2023 Jan 1;7(1):125-139. doi: 10.4049/immunohorizons.2200054. Immunohorizons. 2023. PMID: 36656137 Free PMC article.
A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
An Z, Hsu MA, Gicobi JK, Xu T, Harrington SM, Zhang H, Pavelko KD, Hirdler JB, Lohse CM, Nabavizadeh R, Pessoa RR, Sharma V, Thompson RH, Leibovich BC, Dong H, Lucien F. An Z, et al. Among authors: gicobi jk. J Immunol. 2023 Jun 15;210(12):2029-2037. doi: 10.4049/jimmunol.2200933. J Immunol. 2023. PMID: 37163328
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S. Baumeister SH, et al. Among authors: gicobi jk. Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5. Cancer Immunol Res. 2019. PMID: 30396908 Free PMC article. Clinical Trial.
Responses to 10 common criticisms of anti-racism action in STEMM.
Gosztyla ML, Kwong L, Murray NA, Williams CE, Behnke N, Curry P, Corbett KD, DSouza KN, Gala de Pablo J, Gicobi J, Javidnia M, Lotay N, Prescott SM, Quinn JP, Rivera ZMG, Smith MA, Tang KTY, Venkat A, Yamoah MA. Gosztyla ML, et al. PLoS Comput Biol. 2021 Jul 15;17(7):e1009141. doi: 10.1371/journal.pcbi.1009141. eCollection 2021 Jul. PLoS Comput Biol. 2021. PMID: 34264941 Free PMC article. No abstract available.
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation.
Gicobi JK, Mao Z, DeFranco G, Hirdler JB, Li Y, Vianzon VV, Dellacecca ER, Hsu MA, Barham W, Yan Y, Mansfield AS, Lin Y, Wu X, Hitosugi T, Owen D, Grams MP, Orme JJ, Lucien F, Zeng H, Park SS, Dong H. Gicobi JK, et al. Sci Adv. 2023 Nov 17;9(46):eadi2414. doi: 10.1126/sciadv.adi2414. Epub 2023 Nov 15. Sci Adv. 2023. PMID: 37967193 Free PMC article.